High Throughput Screening
The High Throughput Screening (HTS) Cm e Facility at Beckman Research Institute of City of Hope Core is served as the starting point for drug discovery efforts working in dose collaboration with the stl'I.Jctural biologists, computational chemists, and medicinal chemists that comprise our Drug Discovery and Stl'I.Jctural Biology to bridge the gap between the basic discovery of promising new therapeutic targets and the development of new life-saving, life-improving drugs for patients with cancer and diabetes.
HTS Core occupies over 1000 square feet of laboratory space and facilitates. It offers services of assay development and optimization, high throughput screening, and lead identification and characterization We currently have a diverse small molecule screening library of over 200,000 compounds available, including selected focused libraries of approved drugs, pharmacologically active molecules and kinase inhibitors among others. The in-house collection of novel and diversified compound libraries is designed for discovering novel drug-like molecules that can be further refined and optimized into new therapeutics. The HTS Core has fully automated HTS system for the screening process, using a centralized scheduling softv,,are to integrate and control the si, instruments, induding Echo 650T Acoustic Liquid Dispenser and PerkinElmer Et1Sight Plate Reader. In addition, the cell-based screening services consist of High Content Screening (HCS) system. kinase activity profiling, a11d in-house NCl-60 human cancer cell line assay. These cutting-edge technologies are utilized for drug lead identification and characterization.
David Kwon
Zhe Joe Wang
Contact the Team
The High Throughput Screening {HTS) Core Facility at Beckman Research Institute of City of Hope occupies over 1000 square feet of laboratory space and faciitates. It offers services of assay development and optimization, high throughput screening, and lead identification and characterization. We currently have a diverse small molecule screening library of over 200,000 compounds available, including selected focused libraries of . approved drugs, pharmacologically active molecules and kinase inhibitors among others. The in-house collection of novel and diversified compound libraries Is designed for discovering novel drug-like molecules that can be further refined and optimized into new therapeutics.
The HTS Core has a fully automated HTS system for the screening process, using a centralized scheduling software to integrate and control the six instruments, induding Echo 650T Acoustic Liquid Dispenser and PerkinElmer EnSight Plate Reader. In addition, the cell-based screening se1vices consist of High Content Screening (HCS) system, kinase activity p,ofiling. and in-house NCl-60 human cancer cell line assay. These cutting-edge technologies are utilized for drug lead identification and characterization. The HTS Core nas nighly trained and experienced staff, advanced equipment, and chemical library collection. The combined expertise and technology increase cost-effectiveness and productivity in services. Investigators also benefit from the cumu lative skills and experience.
Please contact Dr. Holly Yin at hoyin@coh.org.
In a given year, City of Hope conducts more than 400 clinical trials enrolling more than 6,000 patients.
Jiménez-Romero, C., Rodriguez, A., & Nam, S.
Könst, Z. A., Szklarski, A. R., Pellegrino, S., Michalak, S. E., Meyer, M., Zanette, C., Cencic, R., Nam, S., Horne, D. A., Pelletier, J., Mobley, D. L., Yusupov, M., & Vanderwal, C. D.
Xu, H. Z., Nam, S., Wu, J., Liu, X., Li, H., Gong, Q., Yin, H., Pillai, R., Querfeld, C., Horne, D., Chan, J., Chen, Y., & Rosen, S. T.
Giannouli, V., Lougiakis, N., Kostakis, I., Pouli, N., Marakos, P., Skaltsounis, L., Horne, D. A., Nam, S., Gioti, K., & Tenta, R.
Michalak, S. E., Nam, S., Kwon, D. M., Horne, D. A, & Vanderwal, C. D.
City of Hope is focused on basic and clinical research in cancer, diabetes and other life-threatening diseases.
